Enhanced recovery program for hip and knee replacement reduces death rate: A study of 4,500 consecutive primary hip and knee replacements by Malviya, Ajay et al.
Acta Orthopaedica 2011; 82 (5): 577–581  577
Enhanced recovery program for hip and knee replacement 
reduces death rate
A study of 4,500 consecutive primary hip and knee replacements
Ajay Malviya, Kate Martin, Ian Harper, Scott D Muller, Kevin P Emmerson, Paul F Partington,    
and Mike R Reed
Northumbria Healthcare NHS Foundation Trust, Tyne and Wear, UK
Correspondence: amalviya@nhs.net  
Submitted 10-06-17. Accepted 11-03-22
Open Access - This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, 
distribution, and reproduction in any medium, provided the source is credited.
DOI 10.3109/17453674.2011.618911
Background and purpose   Multimodal techniques can aid early 
rehabilitation and discharge of patients following primary joint 
replacement. We hypothesized that this not only reduces the eco-
nomic burden of joint replacement by reducing length of stay, but 
also helps in reduction of early complications.
Patients and methods We evaluated 4,500 consecutive unselected 
total  hip  replacements  and  total  knee  replacements  regarding 
length  of  hospital  stay,  mortality,  and  perioperative  complica-
tions. The first 3,000 underwent a traditional protocol while the 
other 1,500 underwent an enhanced recovery protocol involving 
behavioral, pharmacological, and procedural modifications.
Results There was a reduction in 30-day death rate (0.5% to 
0.1%, p = 0.02) and 90-day death rate (0.8% to 0.2%, p = 0.01). 
The median length of stay decreased from 6 days to 3 days (p < 
0.001), resulting in a saving of 5,418 bed days. Requirement for 
blood transfusion was reduced (23% to 9.8%, p < 0.001). There 
was a trend of a reduced rate of 30-day myocardial infarction 
(0.8% to 0.5%. p = 0 .2) and stroke (0.5% to 0.2%, p = 0.2). The 
60-day deep vein thrombosis figures (0.8% to 0.6%, p = 0.5) and 
pulmonary embolism figures (1.2% to 1.1%, p = 0.9) were similar. 
Re-admission rate remained unchanged during the period of the 
study (4.7% to 4.8%, p = 0.8).
Interpretation  This  large  observational  study  of  unselected 
consecutive hip and knee arthroplasty patients shows a substan-
tial reduction in death rate, reduced length of stay, and reduced 
transfusion requirements after the introduction of a multimodal 
enhanced recovery protocol.

Accelerated rehabilitation after arthroplasty may reduce mor-
bidity  and  length  of  hospital  stay,  with  increased  satisfac-
tion and safety after discharge (Kehlet and Wilmore 2002). 
Several randomized trials (Reilly et al. 2005, Andersen et al. 
2007, 2008b, Larsen et al. 2008, Essving et al. 2009) have 
show that local anesthetic wound infiltration after total joint 
replacement can reduce hospital stay. A prerequisite for the 
success of these techniques is a multidisciplinary collabora-
tion between patients, surgeons, anesthetists, physiotherapists, 
occupational therapists, and nursing staff. The Golden Jubilee 
Hospital in Glasgow has published results (Kinninmonth et al. 
2009a, b) and their protocol has been shared with and adopted 
by several centers in the UK.
Endpoints, or success criteria, have uniformly been reduc-
tion  in  postoperative  length  of  stay  (LOS),  shorter  conva-
lescence, and rapid functional recovery (Kehlet and Wilm-
ore 2002). It is not clear, however, whether these protocols 
influence early morbidity and death rates after primary joint 
replacement. We introduced such a technique and compared 
its outcome against our previous results.
Patients and methods
The “enhanced recovery” protocol was introduced in May, 
2008. All patients undergoing primary hip replacement (THR) 
and knee replacement (TKR) under the care of 9 surgeons were 
included at 2 separate units within the same hospital unit. Unit 
1 dealt exclusively with relatively fitter patients (ASA 1 and 
2), while unit 2 dealt with all grades of ASA status because of 
better availability of medical and high-dependency care; thus 
historically, unit 2 has carried patients with a longer length 
of stay. The involvement of all treating staff is thought to be 
critical, and our team were educated en masse by early propo-
nents of the technique (Andersen et al. 2008b, Kinninmonth et 
al. 2009). Minor modifications to their protocol were made to 
accommodate local policy. The enhanced recovery technique 
involves behavioral, pharmacological, and procedural modifi-
cations (Table 1). This includes the use of gabapentin, starting 
on the night before surgery, and tranexamic acid (15 mg/kg, 578  Acta Orthopaedica 2011; 82 (5): 577–581
slow intravenous bolus given at induction of anesthesia).
Anesthesis involved the use of low-dose spinal anesthesia 
combined with sedation, or light general anesthesia with the 
patient breathing spontaneously. Local anesthetic infiltration 
technique (Kerr and Kohan 2008) is simple, safe, cheap, and 
requires no special technical skill (Rostlund and Kehlet 2007). 
It was used in all patients after May, 2008.
Intraoperative infiltration of 80 mL 0.125% levobupivicaine 
using  a  standardized  technique  ensures  wide-field  infiltra-
tion to include joint capsule, muscles, fat, and skin. During 
closure, an epidural catheter is placed within the joint to exit 
away from the surgical field, through which a further 20 mL of 
levobupivicaine is infiltrated after closure. A microbiological 
filter is attached and this catheter is used to infuse 3 postopera-
tive boluses of levobupivicaine 4–6 h postoperatively, again 
after a further 6-to 8-h interval, and lastly on the morning of 
day 1, before removal of the catheter.
The  postoperative  boluses  consisted  of  20  mL  levobupi-
vacaine (1.25 mg/mL) for total hip replacement and 40 mL 
levobupivacaine  (1.25  mg/mL)  for  total  knee  replacement. 
The larger volume used for knee replacement was based upon 
the larger intraarticular space in the knee compared to the hip.
To avoid loss of local anesthetic (Nechleba et al. 2005), 
drains were not used in any of the patients. Knee replacements 
received a single wool and crepe bandage and a Cryo-Cuff 
(Aircast; DJO UK Ltd., Guildford, Surrey, UK) was applied 
to the recovery area. This has been shown to enhance and pro-
long analgesia (Andersen et al. 2008b).
Early postoperative mobilization started within the first 3–5 
h, aiming at discharge to home once the patient was indepen-
dently mobile with the help of appropriate walking aids and 
the standard unchanged hospital discharge criteria had been 
met. Patients were educated to expect some discomfort, and 
were required to be active participants in their recovery. Posi-
tive encouragement from all team members was considered 
important. Patient education is considered a key component of 
the enhanced recovery protocol and a common message was 
transmitted by each member of the team at various stages of 
preoperative assessment. Currently, an information DVD is 
provided to every patient at the time of booking for surgery.
Postoperative analgesia included gabapentin (300 mg BD 
for 5 days) and oxycontin (5–20 mg twice daily for 2 days) fol-
lowed by tramadol (50–100 mg every 4–6 h). Post-discharge 
pain treatment was similar for both groups, with paracetamol, 
NSAIDs, and weak opioids only. Patients were reassured that 
despite earlier discharge they had not been abandoned, and 
they were all supplied with ward contact details and recom-
mendations if they had any concerns.
Venous thromboembolism prophylaxis changed during the 
study period—from mechanical and aspirin to extended tinza-
parin, in keeping with the evolving NICE guidance. 
Hospital episode statistics (HES) on NHS patients are col-
lected by all healthcare providers in the UK (including inde-
pendent  hospitals).  They  describe  each  patient  episode  in 
terms  of  medical  diagnosis  and  complication  codes  (Inter-
national  Statistical  Classification  of  Diseases  and  Related 
Health Problems (tenth revision), ICD-10 codes) and surgi-
cal procedure (Office of Population, Censuses and Surveys 
Classification of Surgical Operations and Procedures (fourth 
revision), OPCS-4 codes). Individual episode data linked to 
complications, which result in re-admission after a successful 
discharge, are included. By employing the appropriate codes, 
complication rates following primary THRs and TKRs can be 
identified. Data were requested on the incidence of mortality, 
return to theater (RTT) for wound problems, stroke, gastroin-
testinal bleeding (GIB), acute renal failure (ARF), myocardial 
infarction (MI), and thrombocytopenia (TCP) within 30 days 
of the primary procedure, and/or those who were diagnosed as 
having deep vein thrombosis (DVT) or pulmonary embolism 
(PE) within 60 days.
“Enhanced recovery” protocol
Patient and staff education specifically detailing “enhanced recovery” principles.
Pre-admission medication:
–  Gabapentin (300 mg) on the night before surgery (to continue twice daily for 5 days).
–  Dexamethasone—10 mg orally on the night before surgery and 4 mg intravenously at 
induction.
Perioperative urinary catheterization—as per clinical indication.
Low-dose spinal anesthesia: 
–  2–3 mL of 0.25% Bupivacaine (plain) or 2 mL of 0.5% Bupivacaine (heavy).
–  No intrathecal opioids.
Propofol intravenous infusion (0–2.5 µg/mL) ± Ketamine (0.5 mg/kg, slow intravenous bolus).
Paracetamol (1 g intravenously) ± Parecoxib (40 mg intravenously).
Judicious intraoperative fluid and vasopressor administration.
Tranexamic acid (15 mg/kg—slow intravenous bolus at induction; withheld in cases of throm-
boembolic event in the last 6 months).
Intra- and postoperative infiltration of local anesthetic (100 mL levobupivacaine 1.25 mg/mL).
Aim for same-day mobilization.
Discharge when standardized criteria met.
Traditional 
Generic patient and staff education.
General anaesthesia, spinal, or epidural 
according to the preference of the anesthetist 
and consent of the patient.
Perioperative urinary catheterization—stand-
ard intravenous fluid until next day
Mobilization next day.
Patient-controlled opioid analgesia intrave-
nously.
Discharge when standardized criteria were 
met.
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We present the results of the first 1,500 primary hip and knee 
replacement patients who went through the enhanced recovery 
protocol from May, 2008 to November, 2009. We compared 
the results with those from an unselected, consecutive series 
of 3,000 of our own total hip and knee replacement patients 
treated with traditional techniques (January, 2004 to April, 
2008) immediately before the introduction of the enhanced 
recovery protocol.
Orthogeriatric rehabilitation is done within our Trust, and 
is not outsourced to another provider. Thus rehabilitation was 
included in the hospital stay for both groups.
Statistics
The two-tailed unpaired t-test was used to compare the length 
of stay (nights in hospital) between the 2 groups. Chi-squared 
tests were performed to compare the complications in the 2 
groups.
Results
There was a highly significant reduction in 30- and 90-day 
mortality (Table 2). The overall length of stay (LOS) decreased 
from a mean of 8.5 to 4.8 days and from a median of 6 to 3 
days (p < 0.001). Some of the comorbidities were commoner 
in the enhanced recovery group (Table 3).
There was a statistically non-significant reduction in myo-
cardial and cerebrovascular complications (Table 4). Throm-
boembolic renal impairment requiring high-dependency care, 
re-admission,  and  return-to-theater  complications  remained 
unchanged.
 The outcome was similar for both units, with a reduction in 
mean LOS (p < 0.001). The mean LOS (in days) in unit 1 was 
higher than in unit 2, both in the traditional (unit 1: 6.6; unit 2: 
9) and the enhanced recovery group (unit 1: 3.4; unit 2: 5.6), 
reflecting the types of patients operated in the 2 units.
The trend of length of stay over the period of the study 
showed a clear reduction in the median length of stay after 
implementation of the enhanced recovery protocol (Figure 1). 
There was a trend of reduction of the various complications 
over the period of the study (Figure 2). 
The  percentage  of  patients  requiring  blood  transfusion 
decreased  from  23%  in  1,000  consecutive  patients  in  the 
Table 2. Comparison of mortality rates between the 2 groups
  Traditional  Enhanced  p-value
  (n = 3,000)  (n = 1,500)  Chi-squared test
Death (30-day)   15 (0.5%)  1 (0.1%)  0.02
Death (90-day)  25 (0.8%)  3 (0.2%)  0.01
Table 3. Comparison of the demographics between the 2 groups
  Traditional  Enhanced  p-value
  (n = 3,000)  (n = 1,500)  Chi-squared test
Age (years)  69  68 
THR  1,368  630 
TKR  1,632  870 
Gender (M:F)  1,482:1,518  711:789  0.2
Comorbidities     
  Hypertension  921 (31%)  673 (45%)  < 0.001
  AF  143 (5%)    84 (6%)  0.2
  IHD  211 (7%)  113 (8%)  0.5
  IDDM    20 (1%)    18 (1%)  0.07
  NIDDM  205 (7%)  150 (10%)  < 0.001
  COPD    85 (3%)    67 (4%)  0.004
  Alzheimer       6 (0.2%)      5 (0.3%)  0.4
AF: atrial fibrillation; IHD: ischemic heart disease; IDDM: insulin-
dependent diabetes mellitus; NIDDM: non-insulin-dependent diabetis 
mellitus; COPD: chronic obstructive pulmonary disease.
Table 4. Comparison of complications between the 2 groups
  Traditional  Enhanced  p-value
  (n = 3,000)  (n = 1,500)  Chi-squared test
RTT (30-day)    74 (2.5%)  27 (1.8%)  0.2
Stroke (30-day)    14 (0.5%)    3 (0.2%)  0.2
GI bleeding (30-day)    18 (0.6%)    4 (0.3%)  0.1
MI (30-day)    25 (0.8%)    7 (0.5%)  0.2
ARF (30-day) a      1 (0.03%)    2 (0.13%)  0.2
DVT (60-day)    23 (0.8%)    9 (0.6%)  0.5
PE (60-day)    36 (1.2%)  17 (1.1%)  0.9
Re-admission   140 (4.7%)  72 (4.8%)  0.8
RTT: return to theater, GI: gastrointestinal, MI: myocardial infarction, 
ARF: acute renal failure, DVT: deep venous thrombosis, PE: pulmo-
nary embolism
a Requiring admission to high dependency unit.
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Figure 1. Box plot to compare the length of stay between the tradiional 
(Trad) and the enhanced recovery (ER) groups.
 
Grouping of patients. Trad1: first 500; Trad2: 501–1,000; Trad3: 1,001–
1,500; Trad4:  1,501–2001; Trad5:  2,001–2,500; Trad6:  2,501–3,000. 
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immediate pre-enhanced recovery protocol group to 9.8% in 
the post-enhanced recovery group (p < 0.001). There has been 
a uniform tranfusion policy since June, 2007; the earlier tradi-
tional patients were therefore excluded. 
Preoperative dexamethasone was initially part of the proto-
col, but several members of the anesthetic and surgical teams 
were  uncomfortable  with  the  immunosuppressive  proper-
ties and potential consequences of infection. It was therefore 
discontinued midway through the enhanced recovery study 
period. Subanalysis of the return-to-theater rates for wound 
problems revealed an RTT rate of 1.5% (7 of 453) before 
implementation of this change as compared to 1.9% (20 of 
1,047) after it (p = 0.6).
Discussion
The  enhanced  recovery  concept  assumes  that  multimodal 
intervention may reduce stress-induced organ dysfunction and 
the accompanying morbidity that results in the subsequent 
need for hospitalization (Kehlet and Wilmore 2002). We found 
a substantial decrease in mortality and some early complica-
tions following initiation of the enhanced recovery protocol in 
this unselected and consecutive series of 4,500 primary joint 
replacements performed by the same group of surgeons.
Linking of consenting patient records held in the National 
Joint Registry (NJR) to the corresponding records in HES 
has  produced  UK  figures  for  90-day  mortality  following 
primary  joint  replacement  (National  Joint  Registry  2008). 
This  includes  complete  national  data  on  102,179  total  hip 
replacements (THRs) and 111,723 total knee replacements 
(TKRs)  excluding  patellofemoral  joint  replacements  per-
formed between April 1, 2003 and September 30, 2007. The 
data show a 90-day mortality rate following THR and TKR of 
0.7% and 0.5%, respectively. Other reports quote 30-day mor-
tality rates after primary hip and knee arthroplasty of between 
0.24% and 0.85% (Fender et al. 1997, Parvizi et al. 2001a, b) 
and 90-day mortality rates from 0.5% to 1.1% (Seagroatt et 
al. 1991, National Joint Registry 2008). Before the inception 
of the enhanced recovery protocol, we had a 30-day mortality 
rate of 0.5% and a 90-day mortality rate of 0.8%, which have 
decreased to 0.1% (p = 0.02) and 0.2% (p = 0.01), respectively.
We have demonstrated that this technique can be adopted, 
and report a median reduction in length of stay of 3 days and 
a mean of 3.7 days. The enhanced recovery group, therefore, 
had 5,418 bed days less than expected. This is similar to the 
figures reported in other studies (Isaac et al. 2005, Reilly et 
al. 2005, Larsen et al. 2008). In England and Wales, more 
than  120,000  primary  total  hip  and  knee  replacements  are 
performed each year (National Joint Registry 2008). There 
is therefore a potential direct annual saving of approximately 
434,520 bed days throughout the NHS. The average cost of an 
adult elective orthopedic bed has been estimated to be around 
€324 (Jones 2008). This is equivalent to an annual saving 
of approximately €141 million. The reduced length of stay 
allowed more cases to be performed per week without any 
additional bed capacity, and this is reflected in the shorter time 
period taken to reach substantial numbers in the enhanced 
recovery group. The cost effectiveness of joint replacement in 
health economic terms has been well documented (Bozic et al. 
2004), and if the cost benefit of reduced complications is taken 
into account, there would be further potential benefit.
In a meta-analysis, intravenous tranexamic acid has been 
shown to be effective in reducing allogenic blood transfusion 
and blood loss in total hip and knee arthroplasty, without any 
apparent increase in the risk of thromboembolic complica-
tions  such  as  deep  vein  thrombosis,  pulmonary  embolism, 
thrombotic cerebral vascular accident, or myocardial infarc-
tion (Ho and Ismail 2003). It is routinely used in this proto-
col, and we found a reduction in the requirement for blood 
transfusion from 23% in the traditional group to 9.8% in the 
enhanced recovery group. 
A high re-admission rate may be an obvious problem with 
accelerated  discharge  (Larsen  et  al.  2008),  with  reports  of 
30-day  re-admission  rates  of  up  to  13%  (Danish  National 
Board  of  Health  and Assessment  2006).  Our  re-admission 
rates (traditional: 4.7%; enhanced recovery: 4.8%) remained 
unchanged throughout the period of the study. Our return-to-
theater rate was similar to the 2% reported by Husted et al 
(2008). 
To our knowledge, this is the largest reported observational 
study to have direct comparison before and after implemen-
tation of the protocol. In an unselected consecutive group of 
4,500 hip and knee arthroplasty patients, we have demon-
strated a highly significant reduction in death rate, reduced 
length of stay, and reduced transfusion requirements after the 
introduction of a multimodal enhanced recovery protocol.
AM  analyzed  the  data  and  prepared  the  manuscript.  KM  collected  and 
retrieved  the  data  and  performed  data  analysis.  IH  conceived  the  study, 
Figure  2. Trend  of  various  complications  through  the  study  period. 
Grouping of patients is explained in the footnote to Figure 1.
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